Organisation paid for research Program year 2025 Source: CMS Open Payments

Sutter Bay Hospitals

Neither a doctor nor a teaching hospital

Research payments

$695,228

350 payments

Through program year 2025, Sutter Bay Hospitals is reported as receiving $695,228 in research payments, across 350 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$111,900	183
2024	Research	$395,413	147
2023	Research	$31,360	2
2022	Research	$7,345	9
2021	Research	$26,338	4
2019	Research	$122,872	5

Breakdown

Who paid Research payments · program years 2019–2025

Kardium Inc. $309,129 301 payments
Janssen Research & Development, LLC $173,754 26 payments
Biogen, Inc. $66,391 4 payments
Otsuka Pharmaceutical Co., Ltd. $57,518 8 payments
TESARO, Inc. $56,481 1 payment
GlaxoSmithKline, LLC. $26,245 3 payments
Takeda Pharmaceuticals U.S.A., Inc. $5,345 6 payments
Immunocore Limited $365 1 payment

Studies the money was for Research payments · program years 2019–2025

70033093Str3001 $173,754 26 payments
Kardium PULSAR DOC-189367 $87,470 180 payments
Cpmc17-Mel01 $56,481 1 payment
An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS) $42,941 1 payment
A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of Astx029 in Subjects With Advanced Solid Tumors $31,180 4 payments
A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of Astx029 in Subjects With Advanced Solid Tumors $26,338 4 payments
A Phase 1B/2 Multicohort Umbrella Study to Evaluate the Safety and Eff $26,245 3 payments
Methodology Study of Novel Outcome Measures to Assess Progression of ALS $11,191 1 payment
Plegridy Observational Program $7,383 1 payment
This Is A Phase III, Prospective, Multicenter Study With Two Study Parts (Epochs) to Evaluate the Efficacy, Safety, and Tolerability of Hyqvia/Hyqvia (Igi, 10% With Recombinant Human Hyaluronidase (Rhuph20) Administered Subcutaneously) for Maintenance Therapy to Prevent Relapse (Epoch 1) and Gammagard Liquid/Kiovig (Immunoglobulin G Intravenous (Igiv) 10% Administered Intravenously) for the Treatment of Cidp (Epoch 2) $5,345 6 payments

What the money was spent on Research payments · program years 2019–2025

Patient care $285,674 277 payments
Overhead $23,455 24 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.